Advertisement


Geertjan van Tienhoven, MD, PhD, on Pancreatic Cancer: Results From the PREOPANC-1 Trial

2018 ASCO Annual Meeting

Advertisement

Geertjan Van Tienhoven, MD, PhD, of the Dutch Pancreatic Cancer Group, discusses phase III study findings on preoperative chemoradiotherapy vs immediate surgery for resectable and borderline resectable pancreatic cancer (Abstract LBA4002).



Related Videos

Hematologic Malignancies
Immunotherapy

Meletios A. Dimopoulos, MD, on Waldenström’s Macroglobulinemia

Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, discusses phase III findings on ibrutinib/rituximab vs placebo/rituximab in Waldenström’s macroglobulinemia (Abstract 8003).

Survivorship
Integrative Oncology
Symptom Management

Jun J. Mao, MD, MSCE, on Insomnia in Cancer Survivors: Trial Results

Jun J. Mao, MD, MSCE, of Memorial Sloan Kettering Cancer Center, discusses study findings on the effect of acupuncture vs cognitive behavior therapy in cancer survivors experiencing insomnia (Abstract 10001).

Breast Cancer

Elizabeth A. Mittendorf, MD, PhD, and Lisa A. Carey, MD, on Breast Cancer: Commentary on the TAILORx Trial

Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber/Brigham and Women’s Cancer Center, and Lisa A. Carey, MD, of the University of North Carolina, discuss the impact of new phase III findings on chemoendocrine treatment vs endocrine treatment alone in hormone receptor–positive, HER2-negative, node-negative breast cancer (Abstract LBA1).

Leukemia

Robert J. Kreitman, MD, on Hairy Cell Leukemia: Results From an International Study

Robert J. Kreitman, MD, of the National Cancer Institute, discusses findings on moxetumomab pasudotox in heavily pretreated patients with relapsed or refractory hairy cell leukemia (Abstract 7004).

Gynecologic Cancers
Immunotherapy

Robert L. Coleman, MD, on Ovarian Cancer: Results From an NRG Oncology/Gynecologic Oncology Group Trial

Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on secondary surgical cytoreduction followed by platinum-based combination chemotherapy, with or without bevacizumab, in platinum-sensitive, recurrent ovarian cancer (Abstract 5501).

Advertisement

Advertisement




Advertisement